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Abstract
Mesenchymal stem cell (MSC) therapy offers great potential for treatment of disease through the multifunctional and
responsive ability of these cells. In numerous contexts, MSC have been shown to reduce inflammation, modulate
immune responses, and provide trophic factor support for regeneration. While the most commonly used MSC source,
the bone marrow provides relatively little starting material for cellular expansion, and requires invasive extraction
means, fibroblasts are easily harvested in large numbers from various biological wastes. Additionally, in vitro expansion of fibroblasts is significantly easier given the robustness of these cells in tissue culture and shorter doubling time
compared to typical MSC. In this paper we put forward the concept that in some cases, fibroblasts may be utilized as a
more practical, and potentially more effective cell therapy than mesenchymal stem cells. Anti-inflammatory, immune
modulatory, and regenerative properties of fibroblasts will be discussed in the context of regenerative medicine.
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Introduction
Friedenstein and colleagues were the first to describe
mesenchymal stem cells (MSC) as adherent cells derived
from bone marrow that were capable of forming colonies
and comprising the radioresistant fraction of cells associated with hematopoiesis [1, 2]. There cells are currently
defined as adherent, non-hematopoietic cells expressing
markers such as CD90, CD105, and CD73, while lacking
expression of CD14, CD34, and CD45, and being able to
differentiate into adipocytes, chondrocytes, and osteocytes in vitro after treatment with differentiation inducing agents [3]. Although early studies in the late 1960s
initially identified MSC in the bone marrow [4], more
recent studies have reported these cells can be purified
from various tissues such as adipose [5], heart [6], Wharton’s Jelly [7], dental pulp [8], peripheral blood [9], cord
blood [10], and more recently menstrual blood [11–13].
Studies in the bone marrow showed that although MSC
are the primary cell type that overgrows in in vitro cultures, in vivo MSC are found at a low ratio compared
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to other bone marrow mononuclear cells, specifically,
1:10,000 to 1:100,000 [14]. The physiological role of MSC
still remains to be fully elucidated, with one hypothesis being that bone marrow MSC act as precursors for
stromal cells that make up the hematopoietic stem cell
microenvironment [15–17].
The first clinical use of MSC was reported in a 1995
paper, in which Lazarus et al. reported the use of autologous, in vitro expanded, “mesenchymal progenitor cells”
to treat 15 patients suffering from hematological malignancies in remission. The authors demonstrated that a
10 cc bone marrow sample was capable of 16,000-fold
growth over a 4–7 week in vitro culture. Cell administration was performed in total doses ranging from 1 to
50 × 106 cells and was not causative of treatment associated adverse effects [18]. In a subsequent study from the
same group, the use of MSC to accelerate hematopoietic reconstitution was performed in 28 breast cancer
patients who received high dose chemotherapy. MSC at
concentrations of 1.0–2.2 × 106/kg, were administered
intravenously with no treatment associated adverse
effects. The authors noted that leukocytic and thrombocytic reconstitution occurred at an accelerated rate as
compared to historical controls [19]. It is important to
note that these initial clinical experiences with MSC were
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in patients with oncological indications and no overt
acceleration of cancer progression was noted. This has
been a concern given that MSC are known to be angiogenic [20–25], produce mitogenic/antiapoptotic factors
[26–32], and exert an immune suppressive effect [33–40].
Besides feasibility, these studies were important because
they established the technique for ex vivo expansion and
re-administration.
The demonstration of clinical feasibility, combined with
animal models supporting therapeutic efficacy of MSC
in non-hematopoietic indications [41–48], gave rise to a
series of clinical trials with MSC in a wide range of therapeutic areas ranging from major diseases such as stroke
[49–52], heart failure [53, 54], COPD [55], and liver failure [56], as well as rare diseases such as osteogenesis
imperfecta [57], Hurler syndrome [58], and Duchenne
Muscular Dystrophy [59]. The ability to generate large
amounts of defined MSC starting with a small clinical
sample, to administer without need for haplotype matching, and excellent safety profile, has resulted in a current 367 clinical trials listed on the international registry
clinicaltrials.gov. While some trials have demonstrated
efficacy of MSC, little is known about molecular mechanisms. Initial studies demonstrated ability of certain
MSC types to differentiate into functional tissues that is
compromised as a result of the underlying pathological.
Although MSC appear to be ideal as a source for development of cellular therapeutics, there are several drawbacks. Firstly, MSC are relatively rare cells in tissue, with
bone marrow containing 1:10,000 to 1:100,000 MSC per
nucleated cells [14]. In order to generate therapeutically relevant doses (1–2 million/kg), the MSC need to
undergo massive numbers of cell multiplication in vitro.
This increases both the possibility of mutatgenesis, as
well as loss of activity. Accordingly, tissue sources, such
as fibroblasts, in which larger numbers of cells may be
originally extracted, may serve as an attractive alternative
to MSC. Secondly, fibroblasts typically possess a shorter
doubling time than MSC, allowing for less tissue culture
media use in their expansion, thus reducing cost of production. Finally, MSC generation often involves isolation
and in vitro growth of the cellular product. In contrast,
fibroblasts may be grown without need for isolation of
specific subtypes of cells.

Properties of fibroblasts
Fibroblasts comprise the main cell type of connective
tissue, possessing a spindle-shaped morphology, whose
classical function has historically been believed to produce extracellular matrix responsible for maintaining
structural integrity of tissue. Fibroblasts also play an
important role in proliferative phase of wound healing,
resulting in deposition of extracellular matrix [60, 61].
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During wound healing, scar tissue is formed by fibroblast over proliferation. In embryos, and in some types of
amphibians, scarless healing occurs after injury, by processes which are currently under intense investigation
[62, 63]. With aging, many kinds of tissues and organs
undergo fibrosis gradually, such as fibrosis of skin, lung,
liver, kidney and heart. The process of scar tissue formation is caused by hyperproliferation of fibroblasts, as
well as these cells producing abnormally large amounts
of extracellular matrix and collagens during proliferation
and thereby replacing normal organ structure (parenchyma), leading to functional impairment and scar formation, which may further trigger persistent fibrosis.
The original thinking on fibroblasts was that these cells
possess similar characteristics regardless of their source
of origin, a notion that is no longer believed to be entirely
correct [64]. For example, studies have shown that protein antigens such as MHC II [65], C1q receptor [66],
LR8 [67], and Thy-1 [68], differ in expression based on
tissue origin of fibroblasts. Interestingly, not only origin
of fibroblasts affects markers but also proliferating state.
For example, one study showed that CD40 expression
on fibroblasts was elevated on proliferating fibroblasts
but reduced on non-proliferating cells [69]. Other variations in fibroblasts have been detected in various tissues
for example, lung fibroblasts are known to possess variable expression of both cell surface marker expression, as
well as in their levels of collagen production [70]. Fibroblasts derived from periodontal tissue possess differences
in extracellular matrix production, glycogen pools, and
morphology [71].
At present there is a deficiency in specific and reproducible markers for fibroblasts, which has hampered to
some extent, our knowledge of in vivo functionality [72,
73]. Currently one of the main means of detecting fibroblasts is quantification of vimentin expression. Vimentin,
is major structural component of the intermediate filaments in many cell types, is shown to play an important
role in vital mechanical and biological functions such
as cell contractility, migration, stiffness, stiffening, and
proliferation [74, 75]. One disadvantage of this marker
is that it is also found on endothelial cells of capillaries
that often locate very close to fibroblasts, additionally, it
is found on neurons [76]. Another marker of fibroblasts,
that is preferentially found on cardiac derived fibroblasts
is the collagen receptor Discoidin Domain Receptor 2
(DDR2 [77]). Unfortunately DDR2 has also been found
non-fibroblast cells such as neutrophils [78], dendritic
cells [79, 80], and osteoblasts [81]. Investigators typically
refer to Thy-1, also known as CD90, as a marker associated with fibroblasts. CD90 is comprised of a glycoprotein anchored by a glycosylphosphatidylinositol (GPI)
tail [82], which is found at various levels of expression of
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fibroblasts [70]. Expression of CD90 on fibroblasts has
been detected on cells from mouse and rat lungs, as well
as from reproductive tract and ocular tissues [68, 83–85].
There appears to be correlations between expression of
CD90 and particular function of fibroblasts. For example,
in one study, lung fibroblasts where shown to be heterogenous in expression of CD90. Cells expressing CD90
where more susceptible to apoptosis than cells lacking
its expression. Furthermore it was found that CD90 coaggregated with Fas, a death inducing molecule, on lipid
rafts, allowing for increased ability for apoptosis [86].
In other studies, CD90 expression is related to ability to
produce the inflammatory cytokine IL-6 [87].

Mesenchymal properties of fibroblasts:
differentiation
The therapeutic significance of the ability of MSC to differentiate into various tissues is under debate, with some
arguments being that MSC exert disease inhibiting activity by secretion of soluble factors, while other schools
of thought suggest that MSC actually differentiate into
injured tissue. The possibility that fibroblasts can also differentiate into tissue is intriguing. Classically, the role of
the fibroblast has been perceived to strictly allow for collagen and other ECM deposition, as well as formation of
scar tissue.
The association of fibroblasts with differentiation
potential comes originally from studies showing that
when mechanical stimulation is applied to dermal fibroblast cells encapsulated in alginate beads using a custombuilt bioreactor system for either a 1- or 3-week period
at a frequency of 1 Hz for 4 h/day under hypoxic conditions, chondrogenic differentiation of the fibroblasts
was observed, as indicated by elevated aggrecan gene
expression and an increased collagen production rate
[88]. In vivo ability of fibroblasts to differentiate into
chondrogenic cells was demonstrated in a subsequent
study. The group of Professor An from Rush University
induced disc degeneration in New Zealand white rabbits by annular puncture and after 4 weeks intradiscally
implanted human dermal fibroblasts or saline. Eight
weeks after cellular implantation there was a significant
increase in disc height in the treated compared to control fibroblasts, as well as reduced expression of inflammatory markers, a higher ratio of collagen type II over
collagen type I gene expression, and more intense immunohistochemical staining for both collagen types I and II
[89]. A subsequent study by an independent group where
8 rabbits underwent disc puncture to induce disc degeneration. One month later, cultured fibroblasts, which had
been taken from the skin, were injected into the disc. The
viability and the potential of the injected cells for reproduction were studied histologically and radiologically.
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Cellular formations and organizations indicating to the
histological recovery were observed at the discs to which
fibroblasts were transplanted. The histological findings of
the discs to which no fibroblasts were transplanted, did
not show any histological recovery. Radiologically, no
finding of the improvement was found in both groups.
The fibroblasts injected to the degenerated discs are viable [90].
In addition to differentiation into chondrocytic tissues,
other studies have shown that fibroblasts are capable
of differentiating into other types of cells. In one study,
cultured human adult bronchial fibroblast-like cells (Br)
where assessed in comparison with mesenchymal cell
progenitors isolated from fetal lung (ICIG7) and adult
bone marrow (BM212) tissues. Surface immunophenotyping by flow cytometry revealed a similar expression
pattern of antigens characteristic of marrow-derived
MSCs, including CD34 (−), CD45 (−), CD90/Thy-1
(+), CD73/SH3, SH4 (+), CD105/SH2 (+) and CD166/
ALCAM (+) in Br, ICIG7 and BM212 cells. There was
one exception, STRO-1 antigen, which was only weakly
expressed in Br cells. Analysis of cytoskeleton and matrix
composition by immunostaining showed that lung and
marrow-derived cells homogeneously expressed vimentin and nestin proteins in intermediate filaments while
they were all devoid of epithelial cytokeratins. Additionally, alpha-smooth muscle actin was also present in
microfilaments of a low number of cells. All cell types
predominantly produced collagen and fibronectin extracellular matrix as evidenced by staining with the monoclonal antibodies to collagen prolyl 4-hydroxylase and
fibronectin isoforms containing the extradomain (ED)-A
together with ED-B in ICIG7 cells. Br cells similarly to
fetal lung and marrow fibroblasts were able to differentiate along the three adipogenic, osteogenic and chondrogenic mesenchymal pathways when cultured under
appropriate inducible conditions. Altogether, these data
indicate that MSCs are present in human adult lung.
They may be actively involved in lung tissue repair under
physiological and pathological circumstances [91].
Another study revealing multilineage differentiation
of fibroblasts used cells isolated from juvenile foreskins.
These cells where shown to share a mesenchymal stem
cell phenotype and multi-lineage differentiation potential. Specifically, the investigators demonstrated similar
expression patterns for CD14(−), CD29(+), CD31(−),
CD34(−), CD44(+), CD45(−), CD71(+), CD73/SH3–
SH4(+), CD90/Thy-1(+), CD105/SH2(+), CD133(−)
and CD166/ALCAM(+) in well-established adipose tissue derived-stem cells and foreskin fibroblastic cells by
flow cytometry. Immunostainings showed that fibroblast cells expressed vimentin, fibronectin and collagen; they were less positive for alpha-smooth muscle
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actin and nestin, while they were negative for epithelial
cytokeratins. When cultured under appropriate inducible conditions, both cell types could differentiate along
the adipogenic and osteogenic lineages. Additionally,
fibroblasts demonstrated a higher proliferation potential than mesenchymal stem cells. These findings are of
particular importance, because skin or adipose tissues
are easily accessible for cell transplantations in regenerative medicine [92]. Verification of multilineage differentiation of foreskin fibroblasts was provided by a study in
which foreskin fibroblasts where demonstrated to possess shorter doubling time than MSC, as well as ability
to multiply more than 50 doublings without undergoing
senescence. The cells were positive for the MSC markers
CD90, CD105, CD166, CD73, SH3, and SH4, and could
be induced to differentiate into osteocytes, adipocytes,
neural cells, smooth muscle cells, Schwann-like cells, and
hepatocyte-like cells [93].
Other more detailed studies have evaluated the potential of fibroblasts to differentiate into endodermal cell
lineages. For example, in one publication, fibroblast cells
were isolated from 12- to 14-day-old pregnant mice that
were characterized for their surface markers and tri-lineage differentiation potential. The investigators found that
islet-like cell aggregates (ICAs) were produced in some
cultures, which was confirmed for their pancreatic properties via immunofluorecence for C-peptide, glucagon,
and somatostain. They were positive for CD markersSca1, CD44, CD73, and CD90 and negative for hematopoietic markers-CD34 and CD45 at both transcription
and translational levels. The transcriptional analysis of
the ICAs at different day points exhibited up-regulation
of islet markers (Insulin, PDX1, HNF3, Glucagon, and
Somatostatin) and down-regulation of MSC-markers
(Vimentin and Nestin). They positively stained for dithizone, C-peptide, insulin, glucagon, and somatostatin
indicating intact insulin producing machinery. In vitro
glucose stimulation assay revealed three-fold increase in
insulin secretion as compared to basal glucose with insulin content being the same in both the conditions. In vivo
data on ICA transplantation showed reversal of diabetes
in streptozotocin induced diabetic mice. These results
demonstrated that mouse fibroblast cells are capable of
differentiation into insulin producing cell aggregates [94].
Another study using foreskin fibroblasts assessed
whether these cells can be transdifferentiated into hepatocytes. The investigators demonstrated that when fibroblasts where cultured in distinct media, spheres formed
in Dulbecco’s modified Eagle’s medium (DMEM) containing F12, epidermal growth factor (EGF), and basic
fibroblast growth factor (b-FGF), however fibroblast-like
morphology was attained with the cells where cultured
in DMEM-based growth medium. Both cell populations
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expressed the typical mesenchymal stem cell markers CD90, CD105, and CD73, but the p75 neurotrophin receptor (p75NTR) was detected only in fibroblast
derived spheres. Both types of fibroblasts could differentiate into hepatocyte-like cells, which express typical liver
markers, including albumin and hepatocyte paraffin 1
(Hep Par1), along with liver-specific biological activities.
When plasmids containing the human hepatitis B virus
(HBV) genome were transfected transiently into fibroblasts, differentiated hepatocyte-like cells secrete large
amounts of HBe and HBs antigens [95].

Mesenchymal properties of fibroblasts: immune
modulation
One of the major therapeutic properties of MSC is
believed to be immune modulation. In fact, the original
clinical implementation of MSC where not for treatment of degenerative diseases but for the immune mediated disorder called “graft versus host disease” (GVHD),
which occurs subsequent to allogeneic hematopoietic
transplants in which donor cells begin attacking recipient cells [96, 97]. MSC have also shown promise in other
immunologically mediated conditions such as multiple
sclerosis [98, 99], sepsis [100], type 1 diabetes [101], and
rheumatoid arthritis [102]. Give that fibroblasts appear to
share with MSC surface markers and ability to transdifferentiate into various tissues, it may not be unreasonable
to assess whether fibroblasts possess immune modulatory properties such as MSC do.
One of the first investigations into immune modulatory
activities of fibroblasts compared foreskin fibroblasts to
bone marrow MSC. The investigators found that fibroblasts were unable to provoke in vitro allogeneic reactions, but strongly suppress lymphocyte proliferation
induced by allogeneic mixed lymphocyte culture (MLC)
or mitogens. We show that fibroblasts’ immunosuppressive capacity is independent from prostaglandin E2, IL-10
and the tryptophan catabolising enzyme indoleamine
2,3-dioxygenase and is not abrogated after the depletion
of CD8+ T lymphocytes, NK cells and monocytes [103].
In another study, human foreskin fibroblasts (HFF)
where assessed for immune modulatory potential. It was
demonstrated that HFFs suppressed human peripheral
blood mononuclear cells (PBMC) proliferation stimulated with mitogen or in an allogeneic mixed lymphocyte
reaction comparable to BMSCs. However, HFFs showed
undetectable levels of indoleamine 2,3-dioxygenase and
inducible nitric oxide synthase expression, in contrast
to BMSCs when cocultured with activated PBMCs. To
identify HFF specific immunosuppressive factors, the
investigators performed array profiling of common
cytokines expressed by HFFs and BMSCs alone or when
cocultured with activated PBMCs. Real-time polymerase
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chain reaction analysis confirmed that multiple factors
were upregulated in HFFs cocultured with activated
PBMCs compared with HFFs alone or BMSCs cultured
under the same conditions. Functional assays identified
interferon-α as the major immunosuppressive mediator expressed by HFFs. These results suggest that the
HFFs possess immunosuppressive properties, which are
mediated by alternate mechanisms to that reported for
BMSCs [104].
A more rigorous study attempted to overcome possible
various between different fibroblast cell lines, in order to
assess whether the immune modulatory activity of the
fibroblasts was a peculiarity to the cells used, or whether
it was an overall property of the cell type itself. The investigators used four well-established human fibroblast
strains from three different tissue sources and several
human MSC strains from two different tissue sources to
compare the phenotypic and immunological characteristics of these cells. The investigators found that fibroblast
strains had a similar morphology to MSCs, expressed the
same cell surface markers as MSCs and could also differentiate into adipocytes, chondrocytes and osteoblasts.
Also, similar to MSCs, these fibroblasts were capable
of suppressing T cell proliferation and modulating the
immunophenotype of macrophages. They also showed
that MSCs deposit extracellular matrices of collagen type
I and fibronectin, and express FSP1 in patterns similar
to fibroblasts. Based on currently accepted definitions
for cultured human MSCs and fibroblasts, the investigators could not find any immunophenotypic property that
could make a characteristic distinction between MSCs
and fibroblasts [105].

Clinical use of fibroblasts
Foreskin fibroblasts, together with keratinocytes have
been used clinically for treatment of various non-healing
wounds. One of the earliest studies created a cultured
skin substitute by successive cultivation of fibroblasts
and keratinocytes that were combined within a collagen matrix. This collagen matrix was composed of a
collagen spongy sheet and a collagen gel. The collagen
spongy sheet was designed to produce a honeycomb
structure having many holes in which all holes through
the sheet were filled with collagen gel. This specific structure thereby allows for the nourishment of the cultured
keratinocytes on the surface of the matrix when placed
on the graft bed. In this study, autologous cultured skin
substitute was applied to a 51-year-old man who had sustained a burn injury. Three sheets of the cultured skin
substitute (6 × 9.5 cm) were grafted onto the full-thickness excised wound in the right anterior chest wall. One
week after grafting most of the matrix disappeared and
stratified keratinocytes were seen to have firmly attached
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to the underlying tissue. Five weeks after grafting a cornified epidermal layer was seen. Ten months after grafting a
mature epidermis and a well-differentiated papillary and
reticular dermis replacement were observed. The physical
properties and color of this grafted area resemble those
of normal skin. In the second patient case, autologous
cultured skin substitute was applied to a 30-year-old man
with a scar remaining after tattoo removal. Eight sheets
of the cultured skin substitute (10 × 18 cm) were applied
on an excised wound (thickness, 0.02–0.025 in.) of both
the fore- and upper arms. The histological appearance
of a biopsied skin specimen from the grafted area at
3 months after grafting showed a mature epidermis and
a well-differentiated reticular dermis replacement. The
regenerated skin at 14 months after grafting showed an
excellent result [106].
Numerous other studies have been conducted using
a similar type of approach, which culminated in the
commercial product known as Dermagraft. The FDA
approved Dermagraft® is a sterile, cryopreserved, human
fibroblast-derived dermal substitute generated by the
culture of neonatal dermal fibroblasts onto a bioabsorbable polyglactin mesh scaffold. During the product-manufacturing process, the human fibroblasts proliferate to
fill the interstices of this scaffold and secrete collagen,
other extracellular matrix proteins, growth factors, and
cytokines, creating a three-dimensional human tissue
containing metabolically active living cells. Dermagraft
has been approved for marketing in the United States
for the treatment of diabetic foot ulcers. In addition, the
product is in active development for the treatment of
venous leg ulcers and has been clinically used in a variety
of other indications to stimulate wound healing [107].
Another example of allogeneic fibroblasts in clinical
use is the treatment of the genetic disease recessive dystrophic epidermolysis bullosa, which is characterized by
a mutation leading to reduced collagen VII production.
Patients with this condition possess very fragile skin,
which often blisters and sheds with minimal contact.
A phase II double-blinded randomized controlled trial
of intralesional allogeneic cultured fibroblasts in suspension solution versus suspension solution alone for
wound healing in patients with recessive dystrophic epidermolysis bullosa was reported. Patients were screened
for chronic ulcers and reduced collagen VII expression.
Up to 6 pairs of symmetric wounds were measured and
biopsied at baseline, then randomized to cultured allogeneic fibroblasts in a crystalloid suspension solution
with 2% albumin or suspension solution alone. Ulcer
size, collagen VII protein and messenger RNA expression, anchoring fibril numbers, morphology, and inflammatory markers were measured at 2 weeks and at 3,
6, and 12 months. The investigators reported that all
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wounds healed significantly more rapidly with fibroblasts
and vehicle injections, with an area decrease of 50% by
12 weeks, compared with noninjected wounds. Collagen
VII expression increased to a similar degree in both study
arms in wounds from 3 of 5 patients [108]. Another study
also supported this possible clinical application. Collagen
VII deficient patients were erosions were randomized
1:1, to either a single treatment of 5 × 10(6) fibroblasts
per linear cm of erosion margin or vehicle. All subjects
continued standard wound care. Twenty-six erosions in
11 subjects with recessive dystrophic epidermolysis bullosa were injected; 14 erosions received fibroblasts and
12 vehicle alone. A single series of injections was given at
day 0 and all follow-up visits were completed. Treatment
difference between fibroblasts and vehicle was − 23.5%
[95% confidence interval (CI) − 3.5 to − 43.5, P = 0.025]
at day 7, − 19.15% (95% CI 3.36 to − 41.66, P = 0.089) at
day 14 and − 28.83% (95% CI 7.97 to − 65.63, P = 0.11)
at day 28 [109]. The ability of fibroblasts to replace collagen VII production indicates that it is feasible to clinically
utilize allogeneic cells without need for immune suppression or development of rejection reactions. This is in line
with previous studies that we discussed which suggested
fibroblasts possess similar immunological properties to
MSC, and thus could be used allogeneically.
Several other examples of clinical use of autologous
fibroblasts exist. These include in conditions of gingival repair [110, 111], inhibition of wrinkles [112], and
treatment of acne scars [113]. L AVIV® (azficel-T) is a
FDA approved autologous cellular product indicated for
improvement of the appearance of moderate to severe
nasolabial fold wrinkles in adults. This product involves
administration of 18 million laboratory expanded fibroblasts and is currently in commercial use without an significant side effects associated with injection [114].

Conclusion
Despite the great interest in development of MSC as an
allogeneic cellular therapeutic, the commercially attractive, and medically beneficial properties of allogeneic
fibroblasts have been overlooked, with exception of
dermal regeneration. The authors believe that based on
the literature overviewed, sufficient rational exists for
expanding clinical investigations of fibroblast therapeutics in areas of unmet medical need. Currently, the
company SpinalCyte, of which two of the authors are
members of, is conducting a clinical trial in disc degenerative disease for which enrollment has been completed and interim data is pending. To the knowledge of
the authors, this will be the first allogeneic use of fibroblasts outside of skin conditions. Success of these studies
is likely to advance the clinical translation of fibroblasts
into other areas of regenerative medicine.
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